NCT04084483View on ClinicalTrials.gov

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

August 4, 2019

Primary Completion Date

January 9, 2020

Study Completion Date

January 9, 2020

Conditions
Dry Eye Disease
Interventions
DRUG

K-161

K-161 alternate dosage

OTHER

Placebo (Vehicle)

Placebo solution

Trial Locations (4)

38119

Total Eye Care, P.A., Memphis

92663

Eye Research Foundation, Newport Beach

04240

Central Maine Eye Care, Lewiston

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Kowa Research Institute, Inc.

INDUSTRY